Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Treatment of Hypertension in Primary Care in Spain (TAPAS)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00868881
First received: March 24, 2009
Last updated: July 10, 2009
Last verified: July 2009
  Purpose

Non-interventional,observational and retrospective study assessing the therapeutic and diagnostic attitude followed in primary care for a hypertensive patient depending on his degree of blood pressure control.


Condition
Hypertension

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Treatment of Hypertension in Primary Care in Spain

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Therapeutic and diagnostic attitude followed in primary care for a hypertensive patient depending on his degree of blood pressure control. [ Time Frame: 1 Year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Variation in the Percentage of patients with blood pressure controlled and not controlled during a year of follow-up. [ Time Frame: 1 Year ] [ Designated as safety issue: No ]
  • Clinical profile and cardiovascular risk. [ Time Frame: 1 Year ] [ Designated as safety issue: No ]

Estimated Enrollment: 2160
Study Start Date: March 2009
Study Completion Date: July 2009
Groups/Cohorts
1
Blood Pressure poorly controlled in the previous year and poorly controlled at the inclusion in the study
2
Blood Pressure poorly controlled in the previous year and well controlled at the inclusion in the study.
3
Blood Pressure well controlled in the previous year and well controlled at the inclusion in the study
4
Blood Pressure well controlled in the previous year and poorly controlled at the inclusion in the study
5
Blood Pressure well controlled in the previous year independently of the level of control at the inclusion.
6
Blood Pressure poorly controlled in the previous year independently of the level of control at the inclusion.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients aged 18 years or older who has been diagnosed of primary hypertension and/or treated for hypertension.

Criteria

Inclusion Criteria:

  • Diagnosis of primary hypertension and/or treated for hypertension for one year or more
  • Clinical data of blood pressure measures for the last 12+/- 2 months before inclusion.

Exclusion Criteria:

  • Secondary Hypertension
  • Physical or psychological impairment for the understanding of the information to be given to the patient
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00868881

  Show 167 Study Locations
Sponsors and Collaborators
AstraZeneca
  More Information

No publications provided

Responsible Party: Juan Carlos Palma, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00868881     History of Changes
Other Study ID Numbers: NIS-CES-DUM-2008/2
Study First Received: March 24, 2009
Last Updated: July 10, 2009
Health Authority: Spain: Ethics Committee

Keywords provided by AstraZeneca:
Hypertension
Therapeutic diagnostic attitude
Blood pressure

Additional relevant MeSH terms:
Hypertension
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on November 20, 2014